Developing a universal vaccine to protect against influenza viruses
Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-10873984
This study is working on a new flu vaccine that could protect you from many different types of the virus, making it more effective and longer-lasting, so you won't have to rely on the usual egg-based vaccines.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10873984 on ClinicalTrials.gov |
What this research studies
This research aims to create a universal influenza vaccine that can provide broad protection against various strains of the virus. It focuses on using innovative molecular adjuvants and novel adenoviral vector delivery methods to enhance immune responses. By targeting conserved parts of the influenza virus, the goal is to generate a vaccine that is effective against both seasonal and pandemic influenza strains. Patients may benefit from a more effective and longer-lasting vaccine that does not rely on traditional egg-based production methods.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at high risk for influenza, such as the elderly, immunocompromised individuals, and those with chronic health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a recent influenza vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective influenza vaccine that protects against multiple strains and reduces the risk of pandemics.
How similar studies have performed: Other research has shown promise in developing universal influenza vaccines, but this approach is innovative and aims to address specific limitations of current vaccines.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COUGHLAN, LYNDA — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: COUGHLAN, LYNDA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.